Published by Global Banking & Finance Review®
Posted on July 24, 2025
2 min readLast updated: January 22, 2026
Add as preferred source on GoogleGalderma boosts 2025 sales forecast after 12.2% growth in H1, shares rise 8%. U.S. market remains key despite tariff concerns.
ZURICH (Reuters) -Swiss skin care company Galderma on Thursday raised its outlook for 2025 after posting net sales growth of 12.2% during the first six months, driven by double-digit growth in the United States and international markets.
Galderma said it expected net sales growth at constant currency to be between 12% and 14% this year, up from previous guidance of 10-12%, as it confirmed guidance on its core EBITDA margin of around 23%, again at constant currency.
The company, which floated on the Swiss stock exchange in March 2024, has seen its shares jump by over 140% since then, and the stock leapt by more than 8% after opening.
Chief Executive Officer Flemming Ornskov said the firm's dermatological skincare and injectable aesthetics and in particular its therapeutic dermatology arms had all posted robust growth as Galderma continued to expand its market share.
Ornskov was speaking to Reuters from Miami as the company establishes its new U.S. headquarters there, and he pointed to the growing importance of the United States, where Galderma generates more than 40% of its sales.
"The U.S. is super important to us, and we continue to build out both our infrastructure and our manufacturing there," Ornskov said.
Galderma said it saw as manageable its exposure to announced U.S. tariffs, which are fully factored-in for the full-year, and was confident that it could absorb some further tariff impact and consumer demand-related deterioration.
(Reporting by Dave Graham, Editing by Rachel More)
Galderma expects net sales growth at constant currency to be between 12% and 14% this year, up from previous guidance of 10-12%.
Since its flotation on the Swiss stock exchange in March 2024, Galderma's shares have jumped by over 140%.
The U.S. is extremely important to Galderma, generating more than half of its revenue, and the company is expanding its infrastructure and manufacturing there.
Galderma views its exposure to announced U.S. tariffs as manageable and is confident it can absorb some further tariff impacts and consumer effects.
Galderma's dermatological skincare and injectable aesthetics, particularly its therapeutic dermatology arms, have all posted robust growth.
Explore more articles in the Headlines category
